Crossmark

Real-World Data on the Efficacy of OnabotulinumtoxinA Injections as Prophylactic Treatment for Migraine: A Retrospective Study from Jeddah, Saudi Arabia (2016–2024)

Crossref DOI link: https://doi.org/10.1007/s40122-025-00805-8

Published Online: 2025-12-16

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Attar, Ahmed

Aladdin, Yasser

Hakami, Alqassem

Alqsair, Abdalmajed https://orcid.org/0009-0008-4020-0986
Baeisa, Sulaiman

Alzahrani, Ahmed

Alsimsimi, Ahmed

Alzebaidi, Sarah
License Information

Text and Data Mining valid from 2025-12-16

Version of Record valid from 2025-12-16
More Information

Article History

Received: 19 October 2025

Accepted: 28 November 2025

First Online: 16 December 2025

Change Date: 17 February 2026

Change Type: Update

Change Details: The original online version of this article was revised to update the affiliations for author Ahmed Attar.

Declarations

:

: All authors (Ahmed Attar, Yasser Aladdin, Alqassem Hakami, Abdalmajed Alqsair, Sulaiman Baeisa, Ahmed Alzahrani, Ahmed Alsimsimi and Sarah Alzebaidi) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

: This study received ethical approval from the Institutional Review Board (IRB) of King Abdulaziz Medical City, Jeddah, Saudi Arabia (reference number H-01-R-005). The study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments. An informed consent was given to each patient prior to participating in the study. Confidentiality was maintained by anonymizing patient data and replacing all identifiers with coded serial numbers.

Document is current

Any future updates will be listed below